Evidence map›Paper›PMID 26314959›Full record

ArticleOncotarget2015

MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells.

Hailun Zheng, Renqiang Ma, Qizhi Wang, Pei Zhang, Dapeng Li, Qiangwu Wang, Jianchao Wang, Huabin Li, Hao Liu, Zhiwei Wang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Crucial Roles of miR-625 in Human Cancer.Frontiers in medicine · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hailun ZhengDepartment of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Renqiang MaCancer Center, ENT Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qizhi WangDepartment of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Pei ZhangFaculty of Pharmacy, Bengbu Medical College, Biochemical Drugs Engineering and Technological Research Center of Anhui Province, Bengbu, Anhui, China.
Dapeng LiDepartment of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Qiangwu WangDepartment of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Jianchao WangDepartment of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Huabin LiCancer Center, ENT Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hao LiuFaculty of Pharmacy, Bengbu Medical College, Biochemical Drugs Engineering and Technological Research Center of Anhui Province, Bengbu, Anhui, China.
Zhiwei WangThe Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou, China.
First Affiliated Hospital of Bengbu Medical College · CNBengbu Medical College · CNThe First Affiliated Hospital, Sun Yat-sen University · CNFirst Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) play a critical role in controlling tumor invasion and metastasis via regulating the expression of a variety of targets, which act as oncogenes or tumor suppressor genes. Abnormally expressed miR-625-3p has been observed in several types of human cancers. However, the molecular mechanisms of miR-625-3p-mediated tumorigenesis are largely elusive. Therefore, the aim of this study was to evaluate the biological function and molecular insight on miR-625-3p-induced oncogenesis in colorectal carcinoma (CRC). The effects of miR-625-3p in cell migration and invasion were analyzed by wound healing assay and transwell assay, respectively. In addition, the expression of miR-625-3p and its targets was detected in five human CRC cell lines. In the present study, we found that overexpression of miR-625-3p promoted migration and invasion in SW480 cells, whereas downregulation of miR-625-3p inhibited cell motility in SW620 cells. More importantly, we observed potential binding sites for miR-625-3p in the 3'-untranslated region of suppressor of cancer cell invasion (SCAI). Notably, we identified that overexpression of miR-625-3p inhibited the expression of SCAI, while depletion of miR-625-3p increased SCAI level, suggesting that SCAI could be a target of miR-625-3p. Additionally, we revealed that miR-625-3p exerts its oncogenic functions through regulation of SCAI/E-cadherin/MMP-9 pathways. Our findings indicate the pivotal role of miR-625-3p in invasion that warrants further exploration whether targeting miR-625-3p could be a promising approach for the treatment of CRC.

Indexed as

Cell MovementAtaxin-1Blotting, WesternCell Line, TumorColorectal NeoplasmsGene Expression Regulation, NeoplasticHumansMicroRNAsNeoplasm InvasivenessReal-Time Polymerase Chain ReactionTransfectionAtaxin-1ATXN1 protein, humanMicroRNAsMIRN625 microRNA, humancolorectal carcinomainvasionmigrationmiR-625-3pSCAI

Identifiers

PMID26314959
PMCPMC4695027
OpenAlexW1700071154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.